Pazufloxacin
Based on 1 publication(s) in Google Scholar
Pazufloxacin is an orally active fluoroquinolone antimicrobial agent. Pazufloxacin inhibits DNA gyrase with IC50 values of 0.88 μg/mL (E. coli) and 1.9 μg/mL (P. aeruginosa). Pazufloxacin exhibits broad-spectrum antimicrobial activity, with MIC90 values ranging from 0.025 to 100 μg/mL against Gram-positive and Gram-negative bacteria, non-fermenting bacteria, Legionella spp., and anaerobic bacteria. Pazufloxacin is indicated for research on systemic infections, lung infections, urinary tract infections, and Legionella pneumonia.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 127045-41-4
- 화학식: C16H15FN2O4
- 분자량:318.30
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Pazufloxacin
MoreAll DNA/RNA Synthesis Isoforms
More
Biological Activity
제품 설명
IC50 & Target
|
Quinolone |
In Vitro
Pazufloxacin shows broad-spectrum antibacterial activity with MIC90s ranging from 0.025 to 100 μg/mL against gram-positive bacteria, gram-negative bacteria, non-fermenters, Legionella spp., and anaerobes[1].
Pazufloxacin inhibits DNA gyrase with IC50s of 0.88 μg/mL (E. coli) and 1.9 μg/mL (P. aeruginosa)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Pazufloxacin (5 mg/kg/day; i.p.; twice a day; 7 days) in combination with Sivelestat (HY-17443) reduces bacterial counts and inflammatory cells in the early phase of Legionella pneumonia in A/J mice, but does not significantly improve survival compared to monotherapy[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 127045-41-4
-
분자량 318.30
-
화학식 C16H15FN2O4
-
SMILES
O=C(C(C1=O)=CN2[C@@H](C)COC3=C(C4(N)CC4)C(F)=CC1=C23)O
-
Synonyms
T3761
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Int J Biol Macromol
Reticuline isomerase AKR1B1 with aldo-keto reductase activity and detoxification function from the insect Blaps rhynchopetera. [Abstract]2026 Mar:352:151224. PMID: 41791543
순도&문서
References
[1]. Fukuoka, Y., et al., In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob Agents Chemother, 1993. 37(3): p. 384-92. [Content Brief]
[2]. Muratani, T., M. Inoue, and S. Mitsuhashi, In vitro activity of T-3761, a new fluoroquinolone. Antimicrob Agents Chemother, 1992. 36(10): p. 2293-303. [Content Brief]
[3]. Takei M, et al. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7. [Content Brief]
[4]. Sousa J, et al. First liquid chromatography method for the simultaneous determination of levofloxacin, pazufloxacin, gatifloxacin, moxifloxacin and trovafloxacin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Jul 1;930:104-11. [Content Brief]
[5]. Morinaga Y, et al. In vivo efficacy of sivelestat in combination with pazufloxacin against Legionella pneumonia. Exp Lung Res. 2010 Oct;36(8):484-90. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pazufloxacin Related Classifications
HY-B0724B Related Classifications
Powered by Bioz